|Bid||1.9600 x 4000|
|Ask||2.1900 x 1200|
|Day's Range||2.0350 - 2.1200|
|52 Week Range||1.2500 - 4.4000|
|Beta (5Y Monthly)||1.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 02, 2020 - Mar 08, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Chimerix, Inc. (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that data relating to its dociparstat sodium (DSTAT) program, formerly known as CX-01, were presented at the 61st American Society of Hematology Annual Meeting, in Orlando, FL. The poster, titled “Updated Study Results for CX-01, an Inhibitor of CXCL12/CXCR4, With Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS,” was presented by Eric Huselton, M.D., Assistant Professor of Medicine at the University of Rochester on December 9, 2019. As reported in the published study abstract, 20 patients with refractory myelodysplastic syndrome (MDS) (n = 9) or refractory acute myeloid leukemia (AML) (n = 11) were enrolled of which 15 were considered evaluable for response with a bone marrow biopsy after cycle 2.
If you're interested in Chimerix, Inc. (NASDAQ:CMRX), then you might want to consider its beta (a measure of share...
– Final Data from Phase 2 Randomized Trial of DSTAT in First-line AML Support Enhanced Durability of Response, Event-free Survival and Overall Survival Benefit – – End of Phase.
DURHAM, N.C., Nov. 04, 2019 -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious.
Chimerix, Inc. (CMRX), a biopharmaceutical company focused on accelerating the development of innovative medicines to treat patients with cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Tuesday, November 5, 2019 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2019, and to provide an operational update. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 30.) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ...
Chimerix (CMRX), a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases, today announces an exclusive global license agreement with SymBio Pharmaceuticals, Ltd (SymBio), under which SymBio has exclusively licensed the worldwide rights to develop, manufacture and commercialize brincidofovir in all human indications, excluding the prevention and treatment of smallpox. Moving forward, SymBio will be responsible for all future development and commercialization as well as manufacturing costs associated with brincidofovir in the licensed indications.
DURHAM, N.C., Sept. 27, 2019 -- Chimerix (NASDAQ:CMRX) today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the upcoming 2019 Cantor.
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
Chimerix (CMRX) delivered earnings and revenue surprises of -105.88% and -37.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Pipeline Transformed with Acquisition of Global Rights to Late Stage Oncology Asset (CX-01) with Fast Track and Orphan Drug Designation Phase 3 Trial of CX-01 in Front-Line.
Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chimerix (CMRX), today announced the completion of an exclusive worldwide license of CX-01 from Cantex Pharmaceuticals, Inc. Chimerix intends to move quickly into Phase 3 development of CX-01 for the treatment of Acute Myeloid Leukemia (AML) in the first-line setting. “We are pleased to have made such rapid progress in repositioning the company and transforming our pipeline with this important cancer therapy.
Does Chimerix Inc (NASDAQ:CMRX) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to […]